摘要:
The present application relates to the use of a phthalazinedione in the prevention or treatment of sequelae of a SARS-CoV-2 infection. Pharmaceutical compositions, combinations, advantageous formulation techniques and a method of treatment are disclosed.
摘要:
The present application relates to the use of a phthalazinedione in the prevention or treatment of coronaviral infections. Pharmaceutical compositions, combinations and advantageous formulation techniques are disclosed.
摘要:
5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts for use as corticoid-sparing agent and pharmaceutical combinations comprising said glucocorticoid-sparing agent and a glucocorticoid for use in the prophylaxis and/or treatment of conditions or diseases usually treated with glucocorticoids are disclosed, as well as suitable application forms, pharmaceutical compositions and their prophylactic or therapeutic uses.
摘要:
A new crystalline form of 5-amino-2,3-dihydro-1,4-phthalazinedione (luminol) is provided. Advantageous uses for this crystalline form as a detecting agent or as an agent for forensic purposes are disclosed, as well a pharmaceutical composition containing said crystalline form.
摘要:
A new method for producing a crystalline form of 5-amino-2,3-dihydro-1,4-phthalazinedione (luminol) is provided. Advantageous uses for this crystalline form as a detecting agent or as an agent for forensic purposes are disclosed, as well a pharmaceutical composition containing said crystalline form.
摘要:
The invention relates to the provision of two novel crystalline forms I and II for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt. Surprisingly, it was discovered that form I and form II have differing immunological effects. This advantageous property is useful for immunospecific applications. In addition, both forms have advantageous physicochemical properties, which are useful in the production, further processing and/or use of a pharmaceutical preparation of form I or form II or a mixture of both.